299 related articles for article (PubMed ID: 31586134)
1. Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein.
Xu MM; Ryan P; Rudrawar S; Quinn RJ; Zhang HY; Mellick GD
Acta Pharmacol Sin; 2020 Apr; 41(4):483-498. PubMed ID: 31586134
[TBL] [Abstract][Full Text] [Related]
2. Small molecule-based fluorescent probes for the detection of α-Synuclein aggregation states.
Haque R; Maity D
Bioorg Med Chem Lett; 2023 Apr; 86():129257. PubMed ID: 36966976
[TBL] [Abstract][Full Text] [Related]
3. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
4. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
Kalsoom I; Wang Y; Li B; Wen H
Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
[TBL] [Abstract][Full Text] [Related]
5. Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.
Luk KC; Hyde EG; Trojanowski JQ; Lee VM
Biochemistry; 2007 Nov; 46(44):12522-9. PubMed ID: 17927212
[TBL] [Abstract][Full Text] [Related]
6. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
[TBL] [Abstract][Full Text] [Related]
7. The interaction between alpha-synuclein and mitochondrial dysfunction in Parkinson's disease.
Li HY; Liu DS; Zhang YB; Rong H; Zhang XJ
Biophys Chem; 2023 Dec; 303():107122. PubMed ID: 37839353
[TBL] [Abstract][Full Text] [Related]
8. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
Sahay S; Ghosh D; Singh PK; Maji SK
Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
[TBL] [Abstract][Full Text] [Related]
9. Ellagic Acid Prevents α-Synuclein Aggregation and Protects SH-SY5Y Cells from Aggregated α-Synuclein-Induced Toxicity via Suppression of Apoptosis and Activation of Autophagy.
Ardah MT; Eid N; Kitada T; Haque ME
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948195
[TBL] [Abstract][Full Text] [Related]
10. α-synuclein aggregation and its modulation.
Ghosh D; Mehra S; Sahay S; Singh PK; Maji SK
Int J Biol Macromol; 2017 Jul; 100():37-54. PubMed ID: 27737778
[TBL] [Abstract][Full Text] [Related]
11. Neuropathology of synuclein aggregates.
Duda JE; Lee VM; Trojanowski JQ
J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore modeling and 3D-QSAR study for the design of novel α-synuclein aggregation inhibitors.
Yang J; Hu J; Zhang G; Qin L; Wen H; Tang Y
J Mol Model; 2021 Aug; 27(9):260. PubMed ID: 34432157
[TBL] [Abstract][Full Text] [Related]
13. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
[TBL] [Abstract][Full Text] [Related]
14. Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation.
Oh Y
BMB Rep; 2019 Jun; 52(6):349-359. PubMed ID: 31186086
[TBL] [Abstract][Full Text] [Related]
15. Modulating α-synuclein propagation and decomposition: Implications in Parkinson's disease therapy.
Li B; Xiao X; Bi M; Jiao Q; Chen X; Yan C; Du X; Jiang H
Ageing Res Rev; 2024 Jul; 98():102319. PubMed ID: 38719160
[TBL] [Abstract][Full Text] [Related]
16. Role of neurotoxicants and traumatic brain injury in α-synuclein protein misfolding and aggregation.
Rokad D; Ghaisas S; Harischandra DS; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
Brain Res Bull; 2017 Jul; 133():60-70. PubMed ID: 27993598
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic Insight into the Binding Profile of DCVJ and α-Synuclein Fibril Revealed by Multiscale Simulations.
Kuang G; Murugan NA; Ågren H
ACS Chem Neurosci; 2019 Jan; 10(1):610-617. PubMed ID: 30277753
[TBL] [Abstract][Full Text] [Related]
18. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
[TBL] [Abstract][Full Text] [Related]
19. Update on the association between alpha-synuclein and tau with mitochondrial dysfunction: Implications for Parkinson's disease.
Feng ST; Wang ZZ; Yuan YH; Sun HM; Chen NH; Zhang Y
Eur J Neurosci; 2021 May; 53(9):2946-2959. PubMed ID: 32031280
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic Oligomers and Fibrils Trapped in a Gel-like State of α-Synuclein Assemblies.
Kumar R; Das S; Mohite GM; Rout SK; Halder S; Jha NN; Ray S; Mehra S; Agarwal V; Maji SK
Angew Chem Int Ed Engl; 2018 May; 57(19):5262-5266. PubMed ID: 29524323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
